seraprevir (GP-205) / GinkgoPharma - LARVOL DELTA

Seraprevir and sofosbuvir for treatment of chronic hepatitis C virus infection: a single-arm, open-label, phase 3 trial. (PubMed, J Gastroenterol Hepatol) - "The all-oral, ribavirin-free regimen of seraprevir and sofosbuvir is an effective and well-tolerated treatment option for Chinese patients mono-infected with HCV, including those with a history of interferon treatment."

Clinical • Journal • P3 data • Fibrosis • Hepatitis C Virus • Hepatology • Immunology • Infectious Disease

[VIRTUAL] Safety and efficacy of an all-oral interferon-free regimen of seraprevir, an NS3/4A protease inhibitor and sofosbuvir in patients with chronic hepatitis C virus (HCV) genotype 1: an open-label,multicentre, phase 3 trial (EASL-ILC-I 2020) - "Treatment with the single-tablet sofosbuvir-Seraprevir was highly effective and well tolerated in GT1 chronic HCV infected population without cirrhosis."

Clinical • P3 data • Fibrosis • Hepatitis C Virus • Hepatology • Immunology • Infectious Disease • Respiratory Diseases

Safety and efficacy of an all-oral interferon-free regimen of seraprevir,an ns3/4a protease inhibitor and sofosbuvir in patients with chronic hepatitis c virus (hcv) genotype 1: an open-label,multicentre, phase 3 trial (EASL-ILC 2020) - No abstract available

Clinical • P3 data

Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 2,3,6 Hepatitis C Virus Infection Patients (clinicaltrials.gov) - P2a; N=36; Recruiting; Sponsor: Ginkgopharma CO., LTD

Clinical • Combination therapy • New P2a trial